BioNTech – Signed Exclusive Research Collaboration in April 2022, ... Matinas BioPharma’s product candidates are all in a development stage and are not available for sale or use.

BEDMINSTER, N.J., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic ...

BEDMINSTER, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (MTNB) (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular ...

FDA feedback from Type B meeting reiterated the Agency’s intent to work collaboratively in advancing development of MAT2203 for the treatment of invasive fungal infections (IFIs) Phase 3 trial ...

Near-term data readouts from internal and collaborative programs expected to support advancement of the LNC platform for delivery of nucleic acids FDA feedback from MAT2203 Type B meeting expected ...

Collaborations with BioNTech (mRNA Partner) and National Resilience (Nucleic Acid Platform Partner) Expected to Generate Initial In Vivo Data in 1H 2023 Seeking BARDA Financial Support and FDA ...

Collaborations with BioNTech (mRNA Partner) and National Resilience (Nucleic Acid Platform Partner) Expected to Generate Initial In Vivo Data in 1H 2023 Seeking BARDA Financial Support and FDA ...